



75 YEARS YOUNG, BOLD AND DYNAMIC

Annual Report 2021-2022



CORPORATE INFORMATION

Board Of Directors

MR. SURESH G KARE, Chairman MS. ADITI PANANDIKAR, Managing Director MR. SUNDEEP V BAMBOLKAR, Jt. Managing Director MR. DIVAKAR M GAVASKAR, Independent Director MR. RAJIV P KAKODKAR, Independent Director DR. (MS.) VASUDHA V KAMAT, Independent Director MR. ABHIJIT Y GORE, Independent Director DR. ANAND M NADKARNI, Non-Executive Director

Chief Financial Officer

MR. PRAMOD GHORPADE

Company Secretary & AVP-Legal

MR. JAYSHANKAR MENON

Registrar & Share Transfer Agent

LINK INTIME INDIA PVT. LTD. C 101, 247 Park, LBS Marg, Vikhroli (W), Mumbai 400083

Bankers

CITIBANK N. A. IDBI BANK LTD. DBS BANK AXIS BANK ICICI BANK

KOTAK MAHINDRA BANK LTD. HDFC BANK LTD. SARASWAT CO-OP BANK LTD. STANDARD CHARTERED BANK STATE BANK OF INDIA EMIRATES NBD BANK

Registered Office

Indoco House, 166 CST Road, Kalina, Mumbai 400098. Tel. No.: +91 22 62871000 / 68791250 Website: www.indoco.com

Auditors

M/S GOKHALE & SATHE - Chartered Accountants 308/309, Udyog Mandir No. 1, 7-C Bhagoji Keer Marg, Mahim, Mumbai 400016

Company Identification Number

CIN: L85190MH1947PLC005913





MESSAGE FROM THE TOP MANAGEMENT

Dear Stakeholders,

We are happy to inform you that all the businesses of our Company have performed well despite various challenges in the global business environment. This robust and sustainable performance during the last two years speaks volumes about smart and intelligent teamwork and above all, effective leadership at every level. However, globally rising inflation, severe disruption in global supply chains, tremendous rise in oil prices, and last but not the least, the Russia-Ukraine war are events playing havoc with the macro-economic business environment. Just when we believed the COVID-19 related economic impact would ease, these current disruptions have once again posed several challenges to business.

In spite of all the above challenges, the Company grew by 23.4 % with revenues at ₹ 1503 crores, as against ₹ 1217 crores in the previous year. The Domestic Formulation Business grew by 29.7 % with revenues at ₹ 803 crores, as against ₹ 619 crores of previous year. The International Formulation Business grew by 26 % with revenues at ₹ 620 crores, as against ₹ 492 crores of previous year.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBIDTA) to net sales is 21.8% at ₹327 crores, compared to 18.4% at ₹223 crores, last year. Profit After Tax (PAT) is 10.3% at ₹154 crores, as against 7.6% at ₹92 crores, last year.

In the Domestic market, we launched six new products (SKUs), two in the acute segment, Naricover and Dropizin Syrup, one in the chronic segment, Methycal 60 K and three in the sub-chronic segment, Rexidin SRS, Noxa and Subitral.

Indoco was successful in launching ten products in the USA and two in Canada through its partners and has received approval of five ANDAs in FY 21-22. The Company was amongst the first few generic companies to launch two products on the day of patent expiry. It is a matter of great pride that Indoco is the only company to launch the generic version of Lacosamide Injection in the US market.

Indoco is committed to building a healthier world by providing quality medicines made available at an affordable price. In these challenging times, we have enhanced our supply chain capabilities and are expanding our manufacturing facilities to meet the ever increasing demand and ensure continuous supply of medicines to needy patients.

Indoco keeps alive its CSR mission by reaching out to the needy with a focus on the welfare of women, the aged and children. We are striving hard to make a positive impact on society and thereby create better lives for a brighter future.

What makes us proud is the relentless hard work and collaborative efforts of Indocoites, along with the support of our stakeholders, including shareholders, customers, bankers, and the medical fraternity globally, who have helped us build a great organization. To all of them we are ever so grateful.

Thanking you all,

Suresh G Kare Chairman



Aditi Panandikar Managing Director




mounde

Sundeep V Bambolkar Jt. Managing Director



BUSINESS HIGHLIGHTS INDIA BUSINESS

Specialised Marketing Divisions	Over 3,00,00 Prescrib Doctor across Ir	ing No. rs in Denta	Segment	83 Million prescriptions annually (IQVIA Medical Audit Prescription Data)	24 Depots and Branches
555 BRANDS amongst the 5 in their RESPECTIVE THERAPEUTIC SEGMENTS	RANKIN 200 Digvia (MAT Jun'22	IG IN INDIA 27, WAWACS SSA Audit (MAT Jul'22)	New launches through in-house development in India	5 Branner	anking
CYCLOPAM	febrex plus	SENSODENT-K	karvol [°] plus	АТМ	OXIPOD
cital	SENSOFORM	SENSODENT KF	ALOJA	GLYCHEK	KIDODENT
Subitral	Rexidin	MCBM-69	Methycal	HOMIDE	CAL-AID
THERAPEUTIC	SEGMENT CONT 9	% FY 2021-202	2	SALES %	FY 2021-2022




Annual Report 2021-2022


Export

54%

BUSINESS

GLOBAL BUSINESS








The second secon

INDOCO AT A GLANCE







It is not just a journey over the years, but a story of commitment, passion and perseverance of a younger, bolder and dynamic Indoco.

> A journey of healing lives began on August 23, 1947 With passion, aspirations and a commitment to shape the future of healthcare And to fulfil the unmet needs of an unconfined nation.

Today we are younger, younger in aggression Bolder in overcoming hurdles and battling uncertainties And dynamic and innovative making ambition meet imagination.

With empowered, spirited Indocoites Unique, bold and enthusiastic We are on an insurmountable path to achieve our Goals...



INDOCO YOUNG @ 75



Our strengths are our core values and ethical way of doing business. We believe that where we are and where we are going matters to us. Our winning ways are to Challenge, Connect and Commit, which brings a cultural transformation to build a high-performing Indoco.

Transforming the workforce

Talent is essential and every Indocoite is respected for his/her talents and hard work. Indoco's culture serves as the anchor for all we do. It not only ensures collaboration and promotes innovation, but offers our employees a genuine opportunity for professional growth and advancement. By working together effectively, in close collaboration and alignment, we tap into our full potential and drive our success. We don't just build careers, we build leaders from within the organization.



HEALTH & WELLNESS SESSION



CONTENTS

1	Notice	2
2	Directors' Report	42
3	Secretarial Audit Report	68
4	Business Responsibility Report	72
5	Report on Corporate Governance	80
6	Management Discussion and Analysis	107
7	Auditor's Report on Financial Statements (Standalone)	123
8	Balance Sheet (Standalone)	136
9	Statement of Profit and Loss (Standalone)	137
10	Cash Flow Statement (Standalone)	138
11	Statement for Changes in Equity (Standalone)	140
12	Significant Accounting Policies (Standalone)	141
13	Notes to Financial Statements (Standalone)	154
14	Financial Highlights	200
15	Auditor's Report on Financial Statements (Consolidated)	204
16	Balance Sheet (Consolidated)	214
17	Statement of Profit and Loss (Consolidated)	215
18	Cash Flow Statement (Consolidated)	216
19	Statement for Changes in Equity (Consolidated)	218
20	Significant Accounting Policies (Consolidated)	219
21	Notes on Financial Statements (Consolidated)	232



_

INDOCO REMEDIES LIMITED

[CIN: L85190MH1947PLC005913]

Registered Office: Indoco House, 166 CST Road, Kalina, Santacruz (E), Mumbai 400 098. Tel: 022-68321400 / email: compliance.officer@indoco.com / Website: www.indoco.com.

NOTICE

Notice is hereby given that the **Seventy Fifth** Annual General Meeting of the members of **INDOCO REMEDIES LIMITED** will be held on **Thursday, September 22, 2022, at 10.30 a.m.** IST through Video Conferencing ("VC")/ Other Audio Visual Means ("OAVM") to transact the following business:

ORDINARY BUSINESS

- 1. To receive, consider and adopt;
 - (a) The audited standalone financial statement of the Company for the financial year ended March 31, 2022 and the Reports of the Board of Directors and the Auditors thereon;
 - (b) The audited consolidated financial statement of the Company for the financial year ended March 31, 2022 and the Report of the Auditors thereon.
- 2. To declare a Final dividend of ₹ 2.25 (including a one-time special dividend of ₹ 0.75) per equity share for the financial year ended March 31, 2022.
- 3. To appoint a Director in place of Dr. Anand M Nadkarni (DIN- 06881461), who retires by rotation and being eligible, offers himself for re-appointment.
- 4. To re-appoint M/s Gokhale & Sathe, a Firm of Chartered Accountants, (Firm Registration No. 103264W) as Statutory Auditors of the Company and to fix their remuneration.

To consider and if thought fit, to pass the following resolution, with or without modification(s), as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to Section 139, 142 and all other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, (including any statutory modification(s) or re-enactment thereof) and pursuant to the recommendations of the Audit Committee and the Board of Directors of the Company, M/s Gokhale & Sathe, a Firm of Chartered Accountants, (Firm Registration No. 103264W) be and are hereby re-appointed as the Statutory Auditors of the Company for a second term of five consecutive years, who shall hold office from the conclusion of the 75th Annual General Meeting till the conclusion of the 80th Annual General Meeting to be held in the year 2027 at such remuneration, out of pocket expenses and applicable taxes as may be mutually agreed between the Board of Directors (including its committees thereof) and the Auditors.

SPECIAL BUSINESS

5. To re-appoint Ms. Aditi Panandikar (DIN: 00179113) as Managing Director

To consider and if thought fit, to pass the following resolution, with or without modification(s), as a **Special Resolution:**

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198 and 203 read with Schedule V and other applicable provisions if any, of the Companies Act, 2013, the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), Regulation 17(6)(e) of Securities and Exchange